{"id":112427,"date":"2008-11-20T19:28:29","date_gmt":"2008-11-21T00:28:29","guid":{"rendered":"https:\/\/www.send2press.com\/wire\/rexin-g-controls-tumor-growth-and-improves-survival-in-chemotherapy-resistant-soft-tissue-sarcoma-and-osteosarcoma\/"},"modified":"2008-11-20T19:28:29","modified_gmt":"2008-11-21T00:28:29","slug":"rexin-g-controls-tumor-growth-and-improves-survival-in-chemotherapy-resistant-soft-tissue-sarcoma-and-osteosarcoma","status":"publish","type":"post","link":"https:\/\/www.send2press.com\/wire\/rexin-g-controls-tumor-growth-and-improves-survival-in-chemotherapy-resistant-soft-tissue-sarcoma-and-osteosarcoma\/","title":{"rendered":"Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma"},"content":{"rendered":"

NEWS SOURCE: Epeius Biotechnologies Corporation<\/strong><\/p>\n

Phase I\/II & Confirmatory Phase II Studies<\/em><\/p>\n

SAN MARINO, Calif., Nov. 20 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the results of Phase I\/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period up to 9 months. Analysis of safety and efficacy data showed no major toxicity, while documenting significant control of tumor growth. <\/p>\n

\"epeius\"Analysis of efficacy in 42 patients with bone and soft tissue sarcoma showed a dose-response relationship between overall survival and Rexin-G which was highly significant. A confirmatory Phase II study in 17 osteosarcoma patients showed a median overall survival greater than seven months; that is, after failing standard chemotherapies. <\/p>\n

Two patients are disease-free greater than 6 months after surgical resection of residual tumors and Rexin-G given as both neoadjuvant and adjuvant monotherapy. <\/p>\n

These studies indicate that (i) intravenous Rexin-G is safe and well-tolerated, and (ii) Rexin-G controls tumor growth and improves survival in a dose-dependent manner in patients with chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma. <\/p>\n

About Epeius Biotechnologies<\/strong><\/p>\n

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its proprietary targeted delivery systems. <\/p>\n

To learn more about Rexin-G® and Epeius Biotechnologies’ pipeline of proprietary compounds currently available for clinical development, please visit us at www.epeiusbiotech.com<\/a>. <\/p>\n

News issued by: Epeius Biotechnologies Corporation<\/p>\n

\"Epeius<\/p>\n

Original Image: https:\/\/www.send2press.com\/wire\/images\/08-0421-Epeius_72dpi.jpg<\/a><\/small><\/p>\n

# # # <\/p>\n

Original Story ID: (4506) :: 2008-11-1120-005<\/small><\/p>\n

Original Keywords: Epeius Biotechnologies Corporation, intravenous Rexin-G, biopharmaceutical company, genetic medicine, targeted gene delivery systems, chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, cancers, Dr. Sant P. Chawla, CTOS 14th annual meetings held in London UK Epeius Biotechnologies Corporation <\/small><\/p>\n

NEWS SOURCE: Epeius Biotechnologies Corporation<\/strong> | Published: 2008-11-20 19:28:29<\/p>\n","protected":false},"excerpt":{"rendered":"

SAN MARINO, Calif., Nov. 20 (SEND2PRESS NEWSWIRE) — Epeius Biotechnologies announced today the results of Phase I\/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period up to 9 months.<\/p>\n","protected":false},"author":9780,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"singles-wide.php","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[19937],"tags":[],"class_list":["post-112427","post","type-post","status-publish","format-standard","hentry","category-press-releases-archive","has-post-title","has-post-date","no-post-category","no-post-tag","no-post-comment","has-post-author"],"acf":[],"views":454,"_links":{"self":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/112427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/users\/9780"}],"replies":[{"embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/comments?post=112427"}],"version-history":[{"count":0,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/posts\/112427\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/media?parent=112427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/categories?post=112427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.send2press.com\/wire\/wp-json\/wp\/v2\/tags?post=112427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}